HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $10 price target.
March 20, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Cocrystal Pharma with a $10 price target.
The reiteration of a Buy rating and a maintained price target of $10 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Cocrystal Pharma. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100